Medtronic Bravo
This article was originally published in The Gray Sheet
Executive Summary
U.S. launch of catheter-free esophageal pH monitoring system as a diagnostic for gastroesophageal reflux disease (GERD) is announced May 21. The capsule-sized radiotelemetry device was acquired along with Endonetics in December 2001 (1"The Gray Sheet" Dec. 24, 2001, In Brief). Other Medtronic gastroenterology devices under development include the Gatekeeper GERD repair system, Enterra therapy for gastroparesis and InterStim therapy for bowel control...
You may also be interested in...
Medtronic/Endonetics
Gastroesophageal reflux disease (GERD) technology developer Endonetics, acquired Dec. 19, is conducting U.S. trials of the Gatekeeper reflux repair system. The device non-invasively places a biomaterial to augment the lower esophageal sphincter. The privately held, San Diego firm's Bravo esophageal pH monitoring system is a catheter-free diagnostic for the condition. The two products will complement Medtronic's existing gastroenterology offerings, including the Enterra therapy for gastroparesis and other gastroenterology diagnostics...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.